mercredi 28 septembre 2016

Onco Actu du 28 septembre 2016

3.1.1 Tabac - e-cigs

AACR Presents E-cigarette Webinar to Educate the Public [AACR]

5. Traitements

Iron nanoparticles prompt immune system to attack cancer, Stanford researchers find [Stanford Medicine]

5.10 Traitements - Essais

Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma [EndPoints]

Amgen's multiple myeloma drug falls short in late stage study [Reuters]

5.12 Immunothérapies

Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup [Xconomy]

CICON16: Corrupted by Cancer [CRI]

CICON16: Cancer antigens and the development of personalized immunotherapy approaches [CRI]

CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints [CRI]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214 [BMS]

Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier [EndPoints]

Bristol-Myers And Nektar Cast Wide Net In Quest To Find The Right Immunotherapy Combo [Forbes]

Bristol-Myers to test Opdivo with Nektar drug for several cancers [Reuters]

5.3 Traitements - FDA, EMA,...

From FDA expert to biotech insider: The drug industry thrives on the revolving door [STAT]

The FDA's revolving door raises ethical questions [Modern Healthcare]

When Drug Reviewers Leave The FDA, They Often Work For Pharma [Kaiser Health News]

5.4 Traitements - Economie

Pegaspargase for treating acute lymphoblastic leukaemia [NICE]

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases [NICE]

Talimogene laherparepvec for treating unresectable metastatic melanoma [NICE]

Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer [NICE]

Furor Over Drug Prices Puts Patient Advocacy Groups in Bind [NY Times]

5.6 ESMO

Merck KGaA, Darmstadt, Germany to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016 [PRNewswire]

Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the European Society for Medical Oncology (ESMO) 2016 congress [Ipsen]

6.1 Observation

1 in 5 emergency bowel cancer patients had symptoms before diagnosis [Cancer Research UK]

Low cancer symptom awareness linked to lower chance of survival [Cancer Research UK]

Lack of Androgen Receptor Protein May Contribute to Racial Disparities in Triple-negative Breast Cancer Outcomes [AACR]

Concern over bowel cancer patients with symptoms year before diagnosis [The Guardian]

6.11 Patients

Many Cancer Caregivers Report Feeling Unprepared for Caregiving Challenges [NCI]

6.7.3 DMP

Fixing electronic health records is good. Adding scribes is even better [STAT]